Cases of acquired hemophilia A following COVID‐19 vaccines: Cogent safety signal or possible reporting/detection bias? Preliminary evidence from Tuscany, Italy

Author:

Roberto Giuseppe1ORCID,Paoletti Olga1,Ferraro Sara2,Hyeraci Giulia1,Franchini Massimo3,Gini Rosa1ORCID,Focosi Daniele4,Tuccori Marco2ORCID

Affiliation:

1. Epidemiology unit Agenzia Regionale di Sanità della Toscana Florence Italy

2. Department of Clinical and Experimental Medicines, Pharmacovigilance Unit University of Pisa Pisa Italy

3. Division of Hematology and Transfusion Medicine Carlo Poma Hospital Mantua Italy

4. University Hospital of Pisa, Blood Bank of Tuscany North‐West Local Health Unit Pisa Italy

Abstract

AbstractPurposeSeveral case reports of acquired hemophilia A (AHA) following COVID‐19 vaccines were recently published. A possible increased incidence of AHA during the COVID‐19 vaccination campaign was also suggested. We aimed at generating evidence for the preliminary assessment of the association between AHA and COVID‐19 vaccination through an ecological study in one Italian region, Tuscany.MethodsAn ecological study was performed using the population‐based administrative data source of Tuscany. Per each year between 2017 and 2021, we included patients aged 5+ and active into the database as of January 1. Temporal patterns of annual incidence of possible AHA cases and AHA‐tested patients were respectively observed. The rates of possible AHA cases per AHA‐tested patients were calculated in 2021 and 2017–2019, respectively (calendar year 2020 was excluded because non‐representative of the pre‐pandemic era). Age–sex standardization was applied. Poisson's 95% confidence intervals (95% CI) were estimated. Statically significant differences were defined as absence of 95% CI overlap.ResultsIn 2021, standardized incidence of both possible AHA cases (5.6/million subjects/year; 95% CI = 3.4–8.7) and AHA‐tested patients (60.7/1000 subjects/year; 95% CI = 60.4–60.9) showed the lowest point estimates, though only the latter was statistically different compared to previous calendar years. The standardized rate of possible AHA cases per AHA‐tested patients was 9.2/100000 (95% CI = 5.6–14.3) in 2021 and 12.5/100000 (95% CI = 8.2–18.1) during 2017–2019.ConclusionsThese preliminary findings do not support the hypothesis of an increased incidence of AHA cases during the COVID‐19 vaccination campaign. However, in 2021, the still ongoing healthcare access restrictions might have contributed to the low incidence of AHA and laboratory tests observed. Therefore, large‐scale multi‐database studies are warranted.

Publisher

Wiley

Subject

Pharmacology (medical),Epidemiology

Cited by 1 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3